The post Bitcoin Likely to Remain Under Pressure as Massive ETF Outflows Shake the Market appeared first on Coinpedia Fintech News Bitcoin has plunged more than 33% from it’s all-time high of $126K and is now trading around $84K, after briefly dipping to $81K. The recent price declines, combined with growing outflows from Bitcoin ETFs, are raising concerns that it could see further drops.  Bitcoin ETFs See $1 Billion In Outflows  According to a report from …The post Bitcoin Likely to Remain Under Pressure as Massive ETF Outflows Shake the Market appeared first on Coinpedia Fintech News Bitcoin has plunged more than 33% from it’s all-time high of $126K and is now trading around $84K, after briefly dipping to $81K. The recent price declines, combined with growing outflows from Bitcoin ETFs, are raising concerns that it could see further drops.  Bitcoin ETFs See $1 Billion In Outflows  According to a report from …

Bitcoin Likely to Remain Under Pressure as Massive ETF Outflows Shake the Market

Bitcoin Price

The post Bitcoin Likely to Remain Under Pressure as Massive ETF Outflows Shake the Market appeared first on Coinpedia Fintech News

Bitcoin has plunged more than 33% from it’s all-time high of $126K and is now trading around $84K, after briefly dipping to $81K. The recent price declines, combined with growing outflows from Bitcoin ETFs, are raising concerns that it could see further drops. 

Bitcoin ETFs See $1 Billion In Outflows 

According to a report from Bloomberg, investors recently pulled nearly $1 billion from Bitcoin ETFs, marking the second-largest daily outflow for the group of 12 funds. BlackRock’s IBIT led the sell-off with $355 million withdrawn, while Grayscale’s GBTC and Fidelity’s FBTC each saw nearly $200 million in outflows. 

These funds are also on pace for their worst weekly outflow since February, which highlights the growing volatility in the market.

Over the past month, investors have pulled nearly $4 billion from these ETFs, and Bitcoin has dropped about 30% in the same period. Both retail and institutional traders are watching these flows as key signals for managing risk.

According to an analysis by Alex Saunders at Citi Research, every $1 billion withdrawn from Bitcoin ETFs roughly equals to a 3.4% drop in Bitcoin. While inflows can boost Bitcoin’s price, the outflows can also worsen the price drops.

The analyst notes that with long-term investors staying cautious and new investors not in a hurry to buy, the inflows could remain slow. Bitcoin ETFs recorded over $238 million in inflows yesterday.

Record Volume Amid Market Stress

In a recent update, Bloomberg analyst Eric Balchunas highlighted a massive surge in Bitcoin ETF trading volume, reaching a record $11.5 billion in a single day. BlackRock’s IBIT fund alone accounted for $8 billion, marking its own record. 

He explains that while the spike looks wild, it is normal during periods of stress. ETFs often act as “liquidity release valves,” where investors actively adjust positions.

Retail Investors Dominate 

Crypto markets came under pressure after a massive liquidation event wiped out billions in leveraged positions.

Before October, investors rushed into crypto in hopes that the Trump administration would continue to help integrate the industry into mainstream finance. While institutions are now more involved in crypto than ever, retail investors still dominate the market. They hold about 75% of spot-Bitcoin ETF assets, according to Bernstein.

However, the recent outflows from Bitcoin ETFs are still small compared to their $113 billion in total assets. The interest has still not faded as ETF issuers are launching new crypto funds, with 17 ETFs debuting since October 10, with more awaiting SEC approval.

Bitcoin Faces Continued Pressure 

CryptoQuant analysts note that whale activity in Bitcoin futures remains absent, and even retail trading, which has been the main driver recently, is thinning. Trading volumes are low, and liquidity is also weakening. 

So, unless institutional demand returns or retail participation picks up, Bitcoin is likely to remain under pressure, with little chance of a strong near-term rebound.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26